Last updated: February 26, 2026
What is the Drug?
NDC 65862-0692 refers to Sotrovimab, a monoclonal antibody used for treating COVID-19. Approved under Emergency Use Authorization (EUA) by the FDA on May 26, 2021, Sotrovimab functions as a therapeutic for mild to moderate COVID-19 in high-risk populations. It targets the spike protein of SARS-CoV-2, inhibiting viral entry into human cells.
Market Dynamics
Current Market Size
The COVID-19 antibody treatment market experienced rapid expansion during the pandemic:
| Measure |
Data |
| Global COVID-19 therapeutics market (2022) |
Estimated at $35 billion[1] |
| Antibody treatment share (2022) |
Approximately 30% of COVID-19 therapeutics[2] |
| Estimated Sotrovimab revenues (2022) |
$2.2 billion (based on sales estimates)[3] |
Key Competitors
- Regeneron’s Ronapreve (casirivimab/imdevimab)
- Eli Lilly’s Bamlanivimab/Etesevimab
- Lilly’s Bebtelovimab (emergency authorized in May 2022)
- Pfizer’s Paxlovid (antiviral, plays a different role but competes for COVID-19 treatments)
Market share shifts depend critically on EUA authorizations, viral mutations, and supply chain factors.
Regulatory and Efficacy Trends
- The EUA for Sotrovimab was initially granted based on Phase 2/3 trial data showing reduction in hospitalization and death.
- Variants like Omicron reduce efficacy of some monoclonal antibodies, including Sotrovimab. In late 2022, the FDA limited Sotrovimab's use to regions with circulating strains still susceptible to its activity.
- The effectiveness window and regional approvals impact market penetration.
Price History and Projections
Current Pricing
- US Price (2022): Approximately $2,100–$2,200 per dose.
- Average Treatment Cost: About $5,250 for a 2-dose treatment course, assuming two vials per dose.
Price Trends and Future Projections
| Year |
Estimated Price Range |
Notes |
| 2023 |
$2,100 – $2,200 |
Stable, in line with current pricing |
| 2024 |
$1,900 – $2,100 |
Potential discounts due to generic entry or supply negotiations |
| 2025 |
$1,800 – $2,000 |
Market saturation effects, patent considerations, and shift to new treatments |
Factors Impacting Price Projections:
- Patent Expiry: The patent for Sotrovimab is expected to expire around 2027, opening potential for biosimilar competition.
- Manufacturing Cost Reductions: Increased scale and improved production processes could lower costs.
- Market Competition: Introduction of alternative therapies could reduce demand and pressure prices.
- Viral Variants’ Impact: Loss of efficacy against emerging variants could reduce utilization, prompting price reductions.
Future Market Outlook
- The COVID-19 treatment market is transitioning from pandemic emergency use to endemic solutions, which could decrease prices.
- The primary market may decrease from $2 billion+ fluorescence in 2022 to sub-$1 billion levels by 2027 if viral immunity wanes and new treatments replace monoclonal antibodies.
- Biosimilars could lower prices by 30–50% post-patent.
Key Competitive Risks
- Variant Resistance: Reduced efficacy against prevalent strains like BA.4/BA.5 limits market applicability.
- Evolving Treatment Guidelines: Shift toward oral antivirals and vaccines can diminish monoclonal antibody demand.
- Regulatory Changes: Potential restrictions or re-authorizations influence supply and pricing.
Implications for Stakeholders
- Pharmaceutical Companies: Focus on patent protection, biosimilar development, and strategic regional licensing.
- Investors: Monitor variant prevalence, FDA authorization status, and biosimilar pipeline.
- Healthcare Providers: Consider cost, efficacy, and regional availability when choosing therapies.
Key Takeaways
- Sotrovimab has a current estimated market value of approximately $2.2 billion annually in the US.
- Price projections for 2023–2025 remain stable but could decline due to biosimilar competition and demand shifts.
- The evolving viral landscape and regulatory environment will influence market size and pricing over the next three years.
- Patent expiration around 2027 creates potential for significant price reductions post-biosimilar entry.
- The treatment landscape is increasingly dominated by oral antivirals, diminishing monoclonal antibody role.
FAQs
Q1: How does the patent expiry impact the price of Sotrovimab?
A: Patent expiry around 2027 allows biosimilar manufacturers to produce lower-cost alternatives, likely leading to 30–50% price reductions.
Q2: What is the primary market driver for Sotrovimab sales?
A: Its use in high-risk outpatient COVID-19 patients during the early stages of infection.
Q3: How do emerging variants influence market prospects?
A: Variants such as Omicron sublineages reduce monoclonal antibody efficacy, limiting Sotrovimab’s usage and revenue potential.
Q4: Will new therapies replace Sotrovimab?
A: Oral antivirals like Paxlovid and Lagevrio are increasingly preferred, which could lead to declining demand for monoclonal antibodies.
Q5: What regional factors affect Sotrovimab’s market size?
A: Variations in circulating variants, regulatory approvals, and healthcare infrastructure influence regional demand and pricing.
References
[1] Global Data (2022). COVID-19 therapeutics market overview.
[2] IQVIA (2022). Market share analysis for COVID-19 treatments.
[3] Market reports (2022). Sotrovimab sales estimates in the US.
(Additional sources can be provided upon request.)
